Predictors for treatment success and expression of @entity4738 in @entity226 and XXXX .

@entity1 @entity32 @entity16123 @entity4738 @entity404 @entity226 @entity469 @entity2225 @entity89 @entity2760 @entity13221 @entity71992 @entity405 @entity4288
OBJECTIVE: @entity226 ( @entity226 ) and @entity2760 ( @entity2760 ) generally respond well to treatment with glucocorticoids (GC). We sought to determine the value of clinical, histopathologic, immunohistochemical, and genetic findings and the expression of the @entity4738 ( @entity4738 ) for discriminating between @entity1 who achieve complete remission, or partial remission, or who do not improve with glucocorticoid treatment. METHODS: We examined biopsies of the temporal artery from 60 @entity1 , of whom 27 had @entity226 , 13 @entity2760 , and 20 @entity4288 . RESULTS: Of the clinical variables evaluated, @entity89 was correlated with the histologic classification of the biopsies (p < 0.0001). Erythrocyte sedimentation rate was significantly higher in @entity1 with @entity2760 and @entity226 than in @entity1 with @entity4288 (p < 0.0001). There were significant differences between @entity1 with @entity226 versus @entity2760 in the numbers of CD3-, @entity405 -, and @entity404 -positive T cells, in @entity469 -positive monocytes (p < 0.0001), and antigen-presenting cells (p < 0.0001). @entity13221 -positive and @entity2225 -positive cells were absent in @entity1 with @entity2760 but present in @entity1 with @entity226 (p < 0.0001). In @entity32 most monocytes and lymphocytes expressed @entity4738 (88.9%). The number of @entity469 -positive cells and the extent of @entity4738 -staining in chronic @entity32 reflected the success of treatment in logistic regression analysis (p < 0.05). @entity4738 polymorphism showed that more than 90% of @entity1 had the wild-type (homozygote) of the @entity71992 or @entity16123 polymorphism. There was no evidence that this polymorphism influenced response to treatment with GC (Fisher's exact test 1.0). CONCLUSION: Expression of @entity4738 and the presence of @entity2225 -, CD3-, @entity404 -, @entity405 -, @entity469 -, @entity13221 -positive cells and antigen-presenting cells differ between @entity226 and @entity2760 . The presence of @entity469 -positive cells and the extent of @entity4738 -staining in chronic @entity32 are suitable to predict complete remission in @entity226 .
